O-GlcNAcylation, a sweet link to the pathology of diseases

Andrali SS, Qian QW, Özcan S, 2007. Glucose mediates the translocation of neurod1 by O-linked glycosylation. J Biol Chem, 282(21):15589–15596. https://doi.org/10.1074/jbc.M701762200 Ball LE, Berkaw MN, Buse MG, 2006. Identification of the major site of O-linked β-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1. Mol Cell Proteom, 5(2):313–323. https://doi.org/10.1074/mcp.M500314-MCP200 Banerjee PS, Lagerlöf O, Hart GW, 2016. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med, 51:1–15. https://doi.org/10.1016/j.mam.2016.05.005 Bond MR, Hanover JA, 2015. A little sugar goes a long way: the cell biology of O-GlcNAc. J Cell Biol, 208(7):869–880. https://doi.org/10.1083/jcb.201501101 Borghgraef P, Menuet C, Theunis C, et al., 2013. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301l mice. PLoS ONE, 8(12): e84442. https://doi.org/10.1371/journal.pone.0084442 Bray F, Ferlay J, Soerjomataram I, et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6):394–424. https://doi.org/10.3322/caac.21492 Buono R, Longo VD, 2018. Starvation, stress resistance, and cancer. Trends Endocrinol Metab, 29(4):271–280. https://doi.org/10.1016/j.tem.2018.01.008 Butkinaree C, Park K, Hart GW, 2010. O-linked β-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta, 1800(2):96–106. https://doi.org/10.1016/j.bbagen.2009.07.018 Carpenter R, DiChiacchio T, Barker K, 2019. Interventions for self-management of type 2 diabetes: an integrative review. Int J Nurs Sci, 6(1):70–91. https://doi.org/10.1016/j.ijnss.2018.12.002 Cecioni S, Vocadlo DJ, 2013. Tools for probing and perturbing O-GlcNAc in cells and in vivo. Curr Opin Chem Biol, 17(5):719–728. https://doi.org/10.1016/jxbpa.2013.06.030 Champattanachai V, Marchase RB, Chatham JC, 2007. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am J Physiol Cell Physiol, 292(1):C178–C187. https://doi.org/10.1152/ajpcell.00162.2006 Chen YX, Jin L, Xue B, et al., 2017. Nrage induces β-catenin/Arm O-GlcNAcylation and negatively regulates Wnt signaling. Biochem Biophys Res Commun, 487(2):433–437. https://doi.org/10.1016/j.bbrc.2017.04.080 Chetan MR, Thrower SL, Narendran P, 2019. What is type 1 diabetes? Medicine, 47(1):5–9. https://doi.org/10.1016/j.mpmed.2018.10.006 Chou TY, Hart GW, Dang CV, 1995. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem, 270(32): 18961–18965. https://doi.org/10.1074/jbc.270.32.18961 Cooper C, Sommerlad A, Lyketsos CG, et al., 2015. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry, 172(4):323–334. https://doi.org/10.1176/appi.ajp.2014.14070878 Cui C, Zhou XL, Zhang WD, et al., 2018. Is β-catenin a druggable target for cancer therapy? Trends Biochem Sci, 43(8):623–634. https://doi.org/10.1016/j.tibs.2018.06.003 Darley-Usmar VM, Ball LE, Chatham JC, 2012. Protein O-linked β-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol, 52(3):538–549. https://doi.org/10.1016/j.yjmcc.2011.08.009 Dassanayaka S, Jones SP, 2014. O-GlcNAc and the cardiovascular system. Pharmacol Ther, 142(1):62–71. https://doi.org/10.1016/j.pharmthera.2013.11.005 de Jesus T, Shukla S, Ramakrishnan P, 2018. Too sweet to resist: control of immune cell function by O-GlcNAcylation. Cell Immunol, 333:85–92. https://doi.org/10.1016/j.cellimm.2018.05.010 Dubois-Deruy E, Belliard A, Mulder P, et al., 2015. Interplay between troponin T phosphorylation and O-N-acetylglucosaminylation in ischaemic heart failure. Cardiovasc Res, 107(1):56–65. https://doi.org/10.1093/cvr/cvv136 Durning SP, Flanagan-Steet H, Prasad N, et al., 2016. O-linked β-N-acetylglucosamine (O-GlcNAc) acts as a glucose sensor to epigenetically regulate the insulin gene in pancreatic beta cells. J Biol Chem, 291(5):2107–2118. https://doi.org/10.1074/jbc.M115.693580 Ferrer CM, Sodi VL, Reginato MJ, 2016. O-GlcNAcylation in cancer biology: linking metabolism and signaling. J Mol Biol, 428(16):3282–3294. https://doi.org/10.1016/jjmb.2016.05.028 Ferron M, Denis M, Persello A, et al., 2018. Protein O-GlcNAcylation in cardiac pathologies: past, present, future. Front Endocrinol (Lausanne), 9:819. https://doi.org/10.3389/fendo.2018.00819 Gao Y, Miyazaki JI, Hart GW, 2003. The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in Min6 β-cells. Arch Biochem Biophys, 415(2):155–163. https://doi.org/10.1016/s0003-9861(03)00234-0 Graham DL, Gray AJ, Joyce JA, et al., 2014. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology, 79:307–313. https://doi.org/10.1016/j.neuropharm.2013.11.025 Gudala K, Bansal D, Schifano F, et al., 2013. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig, 4(6):640–650. https://doi.org/10.1111/jdi.12087 Ha JR, Hao L, Venkateswaran G, et al., 2014. β-Catenin is O-GlcNAc glycosylated at serine 23: implications for β-catenin’s subcellular localization and transactivator function. Exp Cell Res, 321(2):153–166. https://doi.org/10.1016/j.yexcr.2013.11.021 Harosh-Davidovich SB, Khalaila I, 2018. O-GlcNAcylation affects β-catenin and E-cadherin expression, cell motility and tumorigenicity of colorectal cancer. Exp Cell Res, 364(1):42–49. https://doi.org/10.1016/j.yexcr.2018.01.024 Hurtado MD, Vella A, 2019. What is type 2 diabetes? Medicine, 47(1):10–15. https://doi.org/10.1016/j.mpmed.2018.10.010 Hwang H, Rhim H, 2018. Functional significance of O-GlcNAc modification in regulating neuronal properties. Pharmacol Res, 129:295–307. https://doi.org/10.1016/j.phrs.2017.12.006 Issad T, Masson E, Pagesy P, 2010. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab, 36(6):423–435. https://doi.org/10.1016/j.diabet.2010.09.001 Itkonen HM, Minner S, Guldvik IJ, et al., 2013. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res, 73(16):5277–5287. https://doi.org/10.1158/0008-5472.CAN-13-0549 Jiang JY, Lazarus MB, Pasquina L, et al., 2011. A neutral diphosphate mimic crosslinks the active site of human O-GlcNAc transferase. Nat Chem Biol, 8(1):72–77. https://doi.org/10.1038/nchembio.711 Joiner CM, Li H, Jiang JY, et al., 2019. Structural characterization of the O-GlcNAc cycling enzymes: insights into substrate recognition and catalytic mechanisms. Curr Opin Struct Biol, 56:97–106. https://doi.org/10.1016/j.sbi.2018.12.003 Jones SP, Zachara NE, Ngoh GA, et al., 2008. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation, 117(9):1172–1182. https://doi.org/10.1161/CIRCULATIONAHA.107.730515 Kim C, Nam DW, Park SY, et al., 2013. O-linked β -N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment. Neurobiol Aging, 34(1):275–285. https://doi.org/10.1016/j.neurobiolaging.2012.03.001 Lee TN, Alborn WE, Knierman MD, et al., 2006. Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-β-d-glucosaminidase. Biochem Biophys Res Commun, 350(4):1038–1043. https://doi.org/10.1016/j.bbrc.2006.09.155 Leney AC, el Atmioui D, Wu W, et al., 2017. Elucidating crosstalk mechanisms between phosphorylation and O-GlcNAcylation. Proc Natl Acad Sci USA, 114(35): E7255–E7261. https://doi.org/10.1073/pnas.1620529114 Liberti MV, Locasale JW, 2016. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci, 41(3): 211–218. https://doi.org/10.1016/j.tibs.2015.12.001 Lim S, Haque MM, Nam G, et al., 2015. Monitoring of intra-cellular tau aggregation regulated by OGA/OGT inhibitors. Int J Mol Sci, 16(9):20212–20224. https://doi.org/10.3390/ijms160920212 Lin G, Wang LP, Marcogliese PC, et al., 2019. Sphingolipids in the pathogenesis of Parkinson’s disease and Parkinsonism. Trends Endocrinol Metab, 30(2):106–117. https://doi.org/10.1016/j.tem.2018.11.003 Liu Y, Dai SJ, Xing LJ, et al., 2015. O-linked β-N-acetylglucosamine modification and its biological functions. Sci Bull, 60(12):1055–1061. https://doi.org/10.1007/s11434-015-0816-x Ma ZY, Vocadlo DJ, Vosseller K, 2013. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem, 288(21): 15121–15130. https://doi.org/10.1074/jbc.M113.470047 Macauley MS, Vocadlo DJ, 2010. Increasing O-GlcNAc levels: an overview of small-molecule inhibitors of O-GlcNAcase. Biochim Biophys Acta, 1800(2):107–121. https://doi.org/10.1016/j.bbagen.2009.07.028 Macauley MS, Shan XY, Yuzwa SA, et al., 2010. Elevation of global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem Biol, 17(9):949–958. https://doi.org/10.1016/j.chembiol.2010.07.005 Mailleux F, Gélinas R, Beauloye C, et al., 2016. O-GlcNAcylation, enemy or ally during cardiac hypertrophy development? Biochim Biophys Acta, 1862(12):2232–2243. https://doi.org/10.1016/j.bbadis.2016.08.012 Marotta NP, Cherwien CA, Abeywardana T, et al., 2012. O-GlcNAc modification prevents peptide-dependent acceleration of α-synuclein aggregation. Chembiochem, 13(18):2665–2670. https://doi.org/10.1002/cbic.201200478 Marotta NP, Lin YH, Lewis YE, et al., 2015. O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson’s disease. Nat Chem, 7(11):913–920. https://doi.org/10.1038/nchem.2361 Marsh SA, Collins HE, Chatham JC, 2014. Protein O-GlcNAcylation and cardiovascular (patho)physiology. J Biol Chem, 289(50):34449–34456. https://doi.org/10.1074/jbc.R114.585984 McClain DA, Lubas WA, Cooksey RC, et al., 2002. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc Natl Acad Sci USA, 99(16):10695–10699. https://doi.org/10.1073/pnas.152346899 Ngoh GA, Hamid T, Prabhu SD, et al., 2009. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol, 297(5):H1711–H1719. https://doi.org/10.1152/ajpheart.00553.2009 Özcan S, Andrali SS, Cantrell JEL, 2010. Modulation of transcription factor function by O-GlcNAc modification. Biochim Biophys Acta, 1799(5–6):353–364. https://doi.org/10.1016/j.bbagrm.2010.02.005 Patel M, Horgan PG, McMillan DC, et al., 2018. NF-κB pathways in the development and progression of colorectal cancer. Transl Res, 197:43–56. https://doi.org/10.1016/j.trsl.2018.02.002 Peterson SB, Hart GW, 2016. New insights: a role for O-GlcNAcylation in diabetic complications. Crit Rev Biochem Mol Biol, 51(3):150–161. https://doi.org/10.3109/10409238.2015.1135102 Pinho TS, Verde DM, Correia SC, et al., 2018. O-GlcNAcylation and neuronal energy status: implications for Alzheimer’s disease. Ageing Res Rev, 46:32–41. https://doi.org/10.1016/j.arr.2018.05.003 Ramirez-Correa GA, Ma JF, Slawson C, et al., 2015. Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ sensitivity in diabetic cardiac muscle. Diabetes, 64(10): 3573–3587. https://doi.org/10.2337/db14-1107 Rao XJ, Duan XT, Mao WM, et al., 2015. O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth. Nat Commun, 6:8468. https://doi.org/10.1038/ncomms9468 Rowe EM, Xing V, Biggar KK, 2019. Lysine methylation: implications in neurodegenerative disease. Brain Res, 1707:164–171. https://doi.org/10.1016/j.brainres.2018.11.024 Smet-Nocca C, Broncel M, Wieruszeski JM, et al., 2011. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. Mol Biosyst, 7(5):1420–1429. https://doi.org/10.1039/c0mb00337a Snipelisky D, Chaudhry SP, Stewart GC, 2019. The many faces of heart failure. Card Electrophysiol Clin, 11(1): 11–20. https://doi.org/10.1016/j.ccep.2018.11.001 Tan JZA, Gleeson PA, 2019. The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer’s disease. Biochim Biophys Acta, 1861(4):697–712. https://doi.org/10.1016/j.bbamem.2018.11.013 Teo CF, Wollaston-Hayden EE, Wells L, 2010. Hexosamine flux, the O-GlcNAc modification, and the development of insulin resistance in adipocytes. Mol Cell Endocrinol, 318(1–2):44–53. https://doi.org/10.1016/j.mce.2009.09.022 van Giau V, An SSA, Hulme JP, 2018. Mitochondrial therapeutic interventions in Alzheimer’s disease. J Neurol Sci, 395:62–70. https://doi.org/10.1016/j.jns.2018.09.033 Vosseller K, Wells L, Lane MD, et al., 2002. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in AKT activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA, 99(8): 5313–5318. https://doi.org/10.1073/pnas.072072399 Wang Y, Liu J, Jin X, et al., 2017. O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect. Proc Natl Acad Sci USA, 114(52):13732–13737. https://doi.org/10.1073/pnas.1704145115 Wani WY, Chatham JC, Darley-Usmar V, et al., 2017. O-GlcNAcylation and neurodegeneration. Brain Res Bull, 133:80–87. https://doi.org/10.1016/j.brainresbull.2016.08.002 Watson LJ, Facundo HT, Ngoh GA, et al., 2010. O-linked β-N-acetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci USA, 107(41): 17797–17802. https://doi.org/10.1073/pnas.1001907107 Whelan SA, Dias WB, Thiruneelakantapillai L, et al., 2010. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-linked β-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem, 285(8):5204–5211. https://doi.org/10.1074/jbc.M109.077818 Xu WQ, Zhang X, Wu JL, et al., 2017. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. J Hepatol, 67(2):310–320. https://doi.org/10.1016/jjhep.2017.03.017 Yang SL, Zou LY, Bounelis P, et al., 2006. Glucosamine administration during resuscitation improves organ function after trauma hemorrhage. Shock, 25(6):600–607. https://doi.org/10.1097/01.shk.0000209563.07693.db Yang WH, Park SY, Nam HW, et al., 2008a. NFκB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci USA, 105(45):17345–17350. https://doi.org/10.1073/pnas.0806198105 Yang XY, Ongusaha PP, Miles PD, et al., 2008b. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature, 451(7181):964–969. https://doi.org/10.1038/nature06668 Yi W, Clark PM, Mason DE, et al., 2012. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science, 337(6097):975–980. https://doi.org/10.1126/science.1222278 Yuzwa SA, Macauley MS, Heinonen JE, et al., 2008. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol, 4(8): 483–490. https://doi.org/10.1038/nchembio.96 Zachou G, Armeni E, Lambrinoudaki I, 2019. Lactation and maternal cardiovascular disease risk in later life. Maturitas, 122:73–79. https://doi.org/10.1016/j.maturitas.2019.01.007 Zhu YP, Shan XY, Yuzwa SA, et al., 2014. The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem, 289(50):34472–34481. https://doi.org/10.1074/jbc.R114.601351 Zou LY, Yang SL, Hu SH, et al., 2007. The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels. Shock, 27(4):402–408. https://doi.org/10.1097/01.shk.0000245031.31859.29 Zou LY, Yang SL, Champattanachai V, et al., 2009. Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-κB signaling. Am J Physiol Heart Circ Physiol, 296(2):H515–H523. https://doi.org/10.1152/ajpheart.01025.2008